baseline on individual PREMB-R AM/PM items score derived from an analysis of covariance (ANCOVA) model with treatment as the main effect, and study center and baseline score as covariates.

RESULTS: Of 163 children enrolled across 22 sites, 161 were included in the intent-to-treat population (DR/ER-MPH, n = 81; placebo, n = 80) and 138 completed the study. The mean DR/ER-MPH dose achieved after 3 weeks of treatment was 68.1 mg. Following 3 weeks of treatment, DR/ER-MPH significantly reduced mean individual item scores from baseline versus placebo on all PREMB-R AM items (all P < 0.05 in 3 items: getting ready for bed, getting out of bed, and arguing or struggling in the morning). Additionally, DR/ER-MPH significantly reduced mean individual item scores from baseline on 5 out of 8 PREMB-R PM items (P < 0.01 in 2 items: sitting through dinner and playing quietly) and P < 0.05 in 3 items (inattentive/distractible, transitioning between activities, and settling down/getting ready for bed). There was a trend towards a reduction on 2 other items of the PREMB-R PM (P < 0.09). Distributions of the ratings for each item will be presented. No serious TEAEs were reported; TEAEs were consistent with methylphenidate.

CONCLUSIONS: Post hoc analyses revealed that DR/ER-MPH significantly reduced all PREMB-R AM item scores including “getting out of bed”, and many PREMB-R PM items including “getting ready for bed” in children with ADHD. These findings are worth further exploration.

FUNDING ACKNOWLEDGEMENTS: Ironshore Pharmaceuticals & Development, Inc.

129 Effect of DR/ER-MPH on Caregiver-Reported ADHD Symptom Improvement in Children With ADHD and Caregiver Strain: Results From a Phase 3 Trial

Steven R. Pliszka, MD; Valerie K. Arnold, MD; Andrea Marraffino, PhD; Norberto J. De Sousa, MA; Bev Incledon, PhD; F. Randy Sallee, MD, PhD; Timothy E. Wilens, MD; and Jeffrey H. Newcorn, MD

1 The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
2 University of Tennessee Health Science Center, Memphis, Tennessee, USA
3 Meridien Research, Inc., Maitland, Florida, USA
4 Ironshore Pharmaceuticals & Development, Inc., Camana Bay, Grand Cayman, Cayman Islands
5 Massachusetts General Hospital, Boston, Massachusetts, USA
6 Mount Sinai Medical Center, New York, New York, USA; On behalf of the HLD200-108 Study Group

ABSTRACT: Objective: Evening-dosed DR/ER-MPH (formerly HLD200), a delayed-release and extended-release methylphenidate, was designed to provide efficacy upon awakening and through the evening. The objective was to evaluate whether treatment with DR/ER-MPH in children with attention-deficit/hyperactivity disorder (ADHD): (1) improves caregiver-rated ADHD symptoms, and (2) reduces caregiver strain, versus placebo.

METHOD: Caregiver-rated ADHD symptoms (Conners’ Global Index–Parent [CGI-P]) and caregiver strain (Caregiver Strain Questionnaire [CGSQ]) were assessed as secondary endpoints following 3 weeks of treatment in a randomized, double-blind, multicenter, placebo-controlled, parallel-group, phase 3 trial of DR/ER-MPH in children (6-12 years) with ADHD (NCT02520388). Using the 10-item CGI-P, parents rated their child’s ADHD symptoms on a 4-point scale (0 = never/seldom; 5 = very often/frequently). Caregivers also rated the impact of caring for a child with emotional and behavioral challenges on the 21-item CGSQ (5-point scale: 1 = not at all; 5 = very much). A reduction on individual item and total scores for both measures indicated an improvement.

RESULTS: Of 163 children enrolled across 22 sites, 161 were included in the intent-to-treat population (DR/ER-MPH, n = 81; placebo, n = 80) and 138 completed the study. The mean DR/ER-MPH dose after 3 weeks of treatment was 68.1 mg. Mean CGI-P scores at baseline and CGSQ scores at screening (ie, before washout of prior ADHD therapy) were comparable for both DR/ER-MPH (CGI-P: 22.8, CGSQ: 54.5) and placebo (CGI-P: 21.8; CGSQ: 54.9) groups. After 3 weeks of treatment, caregivers of children on DR/ER-MPH reported significant reductions in CGI-P scores versus those on placebo (least-squares [LS] mean: 12.3 vs 17.4; P < 0.001). Additionally, there was a significant reduction in CGSQ scores after 3 weeks of treatment with DR/ER-MPH versus placebo (LS mean: 41.2 vs 49.1; P < 0.001). Post hoc analyses on the effect of DR/ER-MPH versus placebo on individual items of CGI-P and CGSQ, and the two subscales of CGI-P will be presented. No serious TEAEs were reported and all TEAEs were consistent with those of MPH.

CONCLUSIONS: Caregivers reported significant improvements in their child’s ADHD symptoms and these improvements coincided with reductions in caregiver strain after 3 weeks of treatment on evening-dosed DR/ER-MPH versus placebo.

FUNDING ACKNOWLEDGEMENTS: Ironshore Pharmaceuticals & Development, Inc.